Gilead Sciences, Inc. (NASDAQ:GILD), Director Richard James Whitley sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $78.63, for a total value of $393,150.00. Following the completion of the transaction, the director now directly owns 12,778 shares of the company’s stock, valued at approximately $1,004,734. Gilead Sciences, Inc. (NASDAQ:GILD), shares after opening at $76.73 moved to $79.91 on last trade day and at the end of the day closed at $79.83. Company price to sales ratio in past twelve months was calculated as 8.98 and price to cash ratio as 17.90. Gilead Sciences, Inc. (NASDAQ:GILD), showed a positive weekly performance of 7.76%.
HCA Holdings Inc (NYSE:HCA), Insider A Bruce Moore, Jr. sold 75,174 shares of the company’s stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $52.53, for a total value of $3,948,890.22. Following the sale, the insider now directly owns 133,892 shares of the company’s stock, valued at approximately $7,033,347. HCA Holdings Inc (NYSE:HCA), shares advanced 0.91% in last trading session and ended the day on $52.35. HCA Holdings Inc (NYSE:HCA), return on equity ratio is recorded as -18.70% and its return on assets is 5.40%. HCA Holdings Inc (NYSE:HCA), yearly performance is 27.68%.
Celgene Corporation (NASDAQ:CELG), Insider Perry A. Karsen sold 11,922 shares of the stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $146.78, for a total value of $1,749,911.16. Following the transaction, the insider now directly owns 25,705 shares in the company, valued at approximately $3,772,980. Celgene Corporation (NASDAQ:CELG), shares moved up 0.65% in last trading session and was closed at $148.36, while trading in range of $ 143.85 – 148.72. Celgene Corporation (NASDAQ:CELG), year to date (YTD) performance is -12.20%.
CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Jean Jacques Bienaime sells 2,000 shares of BMRN on 02/04/2013 at an average price of $55.77 a share. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), weekly performance is 4.59%. On last trading day company shares ended up $60.13. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), distance from 50-day simple moving average (SMA50) is -13.90%. Analysts mean target Price for the company is $83.05.